StockData

Coherus Oncology vs Invivyd

CHRS and IVVD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CHRS and IVVD compare

Invivyd is the larger company, worth 2.0 times as much as Coherus Oncology ($151M against $73.9M).

Coherus Oncology grew revenue faster over the last twelve months (61.0% versus 26.3% for Invivyd).

Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −259% at Coherus Oncology.

Invivyd scores higher on the StockData Score (9 against 7 for Coherus Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCHRSIVVD
Size and price
Market cap$73.9M$151M
Share price$0.478$0.513
Change, 1 year−59.8%−78.2%
Change, 5 years−97.4%−98.0%
Beta (5Y)0.882.53
Employees147122
StockData Score
Total score79 (better)
Valuation score33
Growth score2 (better)1
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S1.5× (better)2.6×
P/B1.2×0.8× (better)
FCF yield–−72.6%
Fair value$1.16$0.978
Margin of safety58.8% (better)47.6%
Growth
Revenue growth (TTM)61.0% (better)26.3%
Revenue growth, 5Y average−38.4%–
Net income growth (TTM)−174%–
EPS growth, 5Y average−2.5%–
Profitability
Gross margin68.9%–
Operating margin−312%−193% (better)
Net margin−259%−184% (better)
FCF margin–−188%
Return on equity−146%−95.9% (better)
Return on invested capital–−616%
Financial health
Debt / equity–0.00
Interest coverage−17.5×–
Current ratio1.775.87 (better)
Altman Z-score−12.33−4.86 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield–−0.26%
Shareholder yield0.00% (better)−0.26%
Ownership
Held by institutions45.5%79.0%
Held by insiders1.3%16.7%
Insider net buying, 12 months–−$531K
Short interest, % of float8.3%14.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.